Skip to main content Accessibility help

Olanzapine versus haloperidol in the treatment of schizoaffective disorder: Acute and long-term therapy

  • Pierre V. Tran (a1), Gary D. Tollefson (a1), Todd M. Sanger (a1), Yili Lu (a1), Paul H. Berg (a1) and Charles M. Beasley (a1)...



The effectiveness of antipsychotic monotherapy in schizoaffective disorder is limited, and further constrained by safety concerns.


We aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol.


Data were assessed from 300 DSM – III – R schizoaffective subjects from a larger double-blind prospective international study. Subjects were randomly allocated to six weeks of olanzapine (5–20 mg) or haloperidol (5–20 mg) treatment; responders were followed for up to one year of double-blind, long-term maintenance therapy.


Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol-treated patients on overall measures of efficacy, including clinical response. Significantly fewer olanzapine patients left the study early, and fewer adverse events were observed among those receiving olanzapine. During maintenance, olanzapine-treated patients continued to experience additional improvement, with fewer EPS but more weight gain than those on haloperidol.


Olanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.


Corresponding author

Pierre V. Tran, MD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285. Tel: (317)27: (317) 276–4491; Fax: (317)277–7893


Hide All

Declaration of interest

Sponsored by Eli Lilly and Company.



Hide All
American Psychiatric Association (1997) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.
Arango, V., Emsberger, P., Mariuk, P. M., et al (1990) Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Archives of General Psychiatry, 47, 10381047.
Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672676.
Bymaster, F. P., Rasmussen, K., Calligaro, D. C., et al (1997) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Journal of Clinical Psychiatry, 58 (suppl. 10). 2836.
Glazer, W. M., Morgenstern, H. & Doucette, J. T. (1993) Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Journal of Clinical psychiatry, 54, 133139.
Goff, D. & Baldessarini, R. (1993) Drug interactions with antipsychotic agents. Journal of Clinical Psychopharmacology, 13, 5767.
Goff, D., Amico, E., Dreyfuss, D., et al (1994) A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. American Journal of Psychiatry, 151, 429–131.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (Revised DHEW Pub. (ADM)). Rockville, MD: National Institute for Mental Health.
Kay, S. R., Opter, L. A. & Fiszbein, A. (1992) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems. Inc.
Keck, P. E. Jr., McElroy, S. L. & Strakowski, S. M. (1996) New developments in the pharmacologic treatment of schizoaffective disorder. Journal of Clinical Psychiatry. 57 (suppl. 9). 4148.
Meltzer, H. (1989) Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99, S18S27.
Meltzer, H., Matsubara, S. & Lee, J. (1989) Classification of typical and atypical antipsychotic drugs on the basis of Dopamine D1, D2, and serotonin 2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 283–246.
Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382389.
Moore, N. A., Tye, N. C., Axton, M. S., et al (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics, 262, 545551.
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports. 10, 799812.
Remington, G. J., Addington, D., Colins, E. J., et at (1996) Clozapine: current status and role in the pharmacotherapy of schizophrenia. Canadian Journal of Psychiatry, 41, 161166.
Reyntjens, A., Gelders, Y. G., Hoppenbrouwers, M.-L. J. A., et al (1986) Thymosthenic effects of ritanserin. a centrally acting serotonin-S2 receptor blocker. Drug Development Research, 8, 205211.
Schooler, N. R. & Kane, J. M. (1982) Research diagnoses for tardive dyskinesia (letter). Archives of General Psychiatry, 39, 486487.
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (suppl.). S11S19.
Stefanksi, R. & Goldberg, S. R. (1997) Serotonin 5-HT2 receptor antagonists: Potential in the treatment of psychiatric disorders. CNS Drugs. 7, 388409.
Tandon, R., Shipley, J. E., Greden, J. F., et al (1991) Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms. Schizophrenia Research. 4, 2330.
Tollefson, G. D., Beastey, C. M. Jr., Tran, P. V., et al (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154. 457465.
Tollefson, G. D., Sanger, T. M., Lu, M. K., et al (1997b) Depressive signs and symptoms in schizophrenia – a prospective blinded trial of olanzapine and haloperidol. Archives of General Psychiatry. 55. 250258.
Tran, P. V., Dellva, M. A., Tollefson, G. D., et al (1997) Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry. 58. 205211.
Tran, P. V., Dellva, M. A., Tollefson, G. D., et al (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry, 172. 499505.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Olanzapine versus haloperidol in the treatment of schizoaffective disorder: Acute and long-term therapy

  • Pierre V. Tran (a1), Gary D. Tollefson (a1), Todd M. Sanger (a1), Yili Lu (a1), Paul H. Berg (a1) and Charles M. Beasley (a1)...
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *